Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Abstract
The purpose of this study was to use serial imaging to gain insight into the sequence of pathologic events in Alzheimer's disease, and the clinical features associated with this sequence. We measured change in amyloid deposition over time using serial (11)C Pittsburgh compound B (PIB) positron emission tomography and progression of neurodegeneration using serial structural magnetic resonance imaging. We studied 21 healthy cognitively normal subjects, 32 with amnestic mild cognitive impairment and 8 with Alzheimer's disease. Subjects were drawn from two sources--ongoing longitudinal registries at Mayo Clinic, and the Alzheimer's disease Neuroimaging Initiative (ADNI). All subjects underwent clinical assessments, MRI and PIB studies at two time points, approximately one year apart. PIB retention was quantified in global cortical to cerebellar ratio units and brain atrophy in units of cm(3) by measuring ventricular expansion. The annual change in global PIB retention did not differ by clinical group (P = 0.90), and although small (median 0.042 ratio units/year overall) was greater than zero among all subjects (P < 0.001). Ventricular expansion rates differed by clinical group (P < 0.001) and increased in the following order: cognitively normal (1.3 cm(3)/year) < amnestic mild cognitive impairment (2.5 cm(3)/year) < Alzheimer's disease (7.7 cm(3)/year). Among all subjects there was no correlation between PIB change and concurrent change on CDR-SB (r = -0.01, P = 0.97) but some evidence of a weak correlation with MMSE (r =-0.22, P = 0.09). In contrast, greater rates of ventricular expansion were clearly correlated with worsening concurrent change on CDR-SB (r = 0.42, P < 0.01) and MMSE (r =-0.52, P < 0.01). Our data are consistent with a model of typical late onset Alzheimer's disease that has two main features: (i) dissociation between the rate of amyloid deposition and the rate of neurodegeneration late in life, with amyloid deposition proceeding at a constant slow rate while neurodegeneration accelerates and (ii) clinical symptoms are coupled to neurodegeneration not amyloid deposition. Significant plaque deposition occurs prior to clinical decline. The presence of brain amyloidosis alone is not sufficient to produce cognitive decline, rather, the neurodegenerative component of Alzheimer's disease pathology is the direct substrate of cognitive impairment and the rate of cognitive decline is driven by the rate of neurodegeneration. Neurodegeneration (atrophy on MRI) both precedes and parallels cognitive decline. This model implies a complimentary role for MRI and PIB imaging in Alzheimer's disease, with each reflecting one of the major pathologies, amyloid dysmetabolism and neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Efforts continue to be placed on the early detection of AD as changes in brain chemistry begin to occur 20 years or more prior to the onset of noticeable cognitive symptoms [137,138,139,140].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although these symptoms are new to the individual affected, the brain changes that cause them are thought to begin 20 years or more before symptoms start.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319 · cited 1×
“The automated anatomic labelling (AAL) atlas (Tzourio-Mazoyer et al., 2002) was modified in-house to contain the following labelled regions of interest: right and left parietal, temporal, prefrontal, primary sensory -motor, orbito frontal, anterior cingulate, posterior cingulate/ precuneus and occipital.”
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Diagnostic and Statistical Manual of Mental Disorders
Siegel, L. J., & Fletcher‐Janzem, E. (2008) · Encyclopedia of Special Education · doi:10.1002/9780470373699.speced0655 · Cited by 8,477
What's wrong with Bonferroni adjustments
Perneger, T. V. (1998) · BMJ · doi:10.1136/bmj.316.7139.1236 · Cited by 5,900
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Self-citation
Cited by
Items 201–300 of 1,000
Baker, L. D., Barsness, S. M., Borson, S., Merriam, G. R., Friedman, S. D., Craft, S., & Vitiello, M. V. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1970 · Cited by 138
Cerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 121
Self-citationMaeda, J., Zhang, M.-R., Okauchi, T., Ji, B., Ono, M., Hattori, S., Kumata, K., Iwata, N., Saido, T. C., Trojanowski, J. Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3076-10.2011 · Cited by 136
Racine, A. M., Adluru, N., Alexander, A. L., Christian, B. T., Okonkwo, O. C., Oh, J., Cleary, C. A., Birdsill, A., Hillmer, A. T., Murali, D., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.02.001 · Cited by 136
“…et al., 2009) while others have found associations between amyloid burden and poorer cognitive performance (Kennedy et al., 2012; Rodrigue et al., 2012) and even changing associations based on the disease stage (Chetelat, 2013; Jack et al., 2009; Naslund et al., 2000; Villemagne et al., 2013).”
InfluentialAmyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue
Ni, R., Gillberg, P.-G., Bergfors, A., Marutle, A., & Nordberg, A. (2013) · Brain · doi:10.1093/brain/awt142 · Cited by 133
Association of Midlife Hearing Impairment With Late-Life Temporal Lobe Volume Loss
Armstrong, N. M., An, Y., Doshi, J. J., Erus, G., Ferrucci, L., Davatzikos, C. A., Deal, J. A., Lin, F. R., & Resnick, S. M. (2019) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2019.1610 · Cited by 145
Cerebral perfusion in the predementia stages of Alzheimer’s disease
Binnewijzend, M. A. A., Benedictus, M. R., Kuijer, J. P. A., van der Flier, W. M., Teunissen, C. E., Prins, N. D., Wattjes, M. P., van Berckel, B. N. M., Scheltens, P., & Barkhof, F. (2016) · European Radiology · doi:10.1007/s00330-015-3834-9 · Cited by 132
Does Personality Affect Risk for Dementia? A Systematic Review and Meta-Analysis
Low, L., Harrison, F., & Lackersteen, S. M. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2012.08.004 · Cited by 145
Weakly Supervised Deep Learning for Brain Disease Prognosis Using MRI and Incomplete Clinical Scores
Liu, M., Zhang, J., Lian, C., & Shen, D. (2019) · IEEE Transactions on Cybernetics · doi:10.1109/tcyb.2019.2904186 · Cited by 125
Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease
de Souza, L. C., Corlier, F., Habert, M.-O., Uspenskaya, O., Maroy, R., Lamari, F., Chupin, M., Lehéricy, S., Colliot, O., Hahn-Barma, V., et al. (2011) · Brain · doi:10.1093/brain/awr130 · Cited by 131
Healthy Aging and Dementia: Two Roads Diverging in Midlife?
Irwin, K., Sexton, C., Daniel, T., Lawlor, B., & Naci, L. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00275 · Cited by 124
CSF tau markers are correlated with hippocampal volume in Alzheimer's disease
de Souza, L. C., Marie Chupin, A., Lamari, F., Jardel, C., Leclercq, D., Olivier Colliot, A., Lehéricy, S., Dubois, B., & Sarazin, M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.022 · Cited by 140
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Klunk, W. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 129
Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., Senjem, M. L., Gunter, J. L., Lowe, V., Gregg, B. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000386 · Cited by 125
Self-citationJack, C. R., Therneau, T. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Mielke, M. M., Vemuri, P., Roberts, R. O., Machulda, M. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00323-3 · Cited by 129
Self-citationCerebrovascular disease, beta-amyloid, and cognition in aging
Marchant, N. L., Reed, B. R., DeCarli, C. S., Madison, C. M., Weiner, M. W., Chui, H. C., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.001 · Cited by 127
“The amyloid cascade hypothesis proposes that A! is an initiating factor in the progression toward AD (Hardy and Selkoe, 2002); therefore, in cognitively intact older adults it may be the delayed sequelae of A! deposition, such as regional atrophy or tau aggregation, that produce cognitive deficits (Jack et al., 2009;…”
BackgroundSelf-citation24S-hydroxycholesterol in plasma: A marker of cholesterol turnover in neurodegenerative diseases
Leoni, V., & Caccia, C. (2012) · Biochimie · doi:10.1016/j.biochi.2012.09.025 · Cited by 128
What Goes Down Must Come Up: Role of the Posteromedial Cortices in Encoding and Retrieval
Vannini, P., O'Brien, J., O'Keefe, K., Pihlajamaki, M., LaViolette, P., & Sperling, R. A. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhq051 · Cited by 120
Bernal-Rusiel, J. L., Reuter, M., Greve, D. N., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.049 · Cited by 125
“A popular method to analyze LNI data, e.g. (Fotenos et al., 2005; Fouquet et al., 2009; Frings et al., 2011; Hedman et al., 2011; Hua et al., 2010; Hua et al., 2009; Jack Jr et al., 2009; Josephs et al., 2008; Kalkers et al., 2002; Kasai et al., 2003; Martensson et al., 2012; Paviour et al., 2006; Rosas et al., 2011;…”
InfluentialZhang, S., Han, D., Tan, X., Feng, J., Guo, Y., & Ding, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02845.x · Cited by 121
Aslan, Z., & Akın, M. (2020) · Traitement du signal · doi:10.18280/ts.370209 · Cited by 136
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.006 · Cited by 124
Prevalence of preclinical Alzheimer disease: Comparison of current classification systems
Kern, S., Zetterberg, H., Kern, J., Zettergren, A., Waern, M., Höglund, K., Andreasson, U., Wetterberg, H., Börjesson-Hanson, A., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005476 · Cited by 120
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box
Young, A. L., Oxtoby, N. P., Garbarino, S., Fox, N. C., Barkhof, F., Schott, J. M., & Alexander, D. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00779-6 · Cited by 145
Spatial patterns of brain amyloid- burden and atrophy rate associations in mild cognitive impairment
Tosun, D., Schuff, N., Mathis, C. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2011) · Brain · doi:10.1093/brain/awr044 · Cited by 117
Self-citationDementiaBank: Theoretical Rationale, Protocol, and Illustrative Analyses
Lanzi, A. M., Saylor, A. K., Fromm, D., Liu, H., MacWhinney, B., & Cohen, M. L. (2023) · American Journal of Speech-Language Pathology · doi:10.1044/2022_ajslp-22-00281 · Cited by 106
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 121
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes
Beckett, L. A., Harvey, D. J., Gamst, A., Donohue, M., Kornak, J., Zhang, H., Kuo, J. H., & Initiative, A. D. N. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.002 · Cited by 119
Lim, Y. Y., Jaeger, J., Harrington, K., Ashwood, T., Ellis, K. A., Stoffler, A., Szoeke, C., Lachovitzki, R., Martins, R. N., Villemagne, V. L., et al. (2013) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/act021 · Cited by 110
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Quantitative sodium MR imaging: A review of its evolving role in medicine
Thulborn, K. R. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.11.056 · Cited by 125
Yokoi, T., Watanabe, H., Yamaguchi, H., Bagarinao, E., Masuda, M., Imai, K., Ogura, A., Ohdake, R., Kawabata, K., Hara, K., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00304 · Cited by 116
Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains
Moore, B. D., Chakrabarty, P., Levites, Y., Kukar, T. L., Baine, A.-M., Moroni, T., Ladd, T. B., Das, P., Dickson, D. W., & Golde, T. E. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt121 · Cited by 113
A longitudinal study of brain atrophy over two years in community-dwelling older individuals
Jiang, J., Sachdev, P. S., Lipnicki, D. M., Zhang, H., Liu, T., Zhu, W., Suo, C., Zhuang, L., Crawford, J., Reppermund, S., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.022 · Cited by 122
Fortea, J., Sala‐Llonch, R., Bartrés‐Faz, D., Lladó, A., Solé‐Padullés, C., Bosch, B., Antonell, A., Olives, J., Sánchez‐Valle, R., Molinuevo, J. L., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.017 · Cited by 117
Bao, F., Wicklund, L., Lacor, P. N., Klein, W. L., Nordberg, A. K., & Marutle, A. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.003 · Cited by 126
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Reconsider Alzheimer's disease by the ‘calpain–cathepsin hypothesis’—A perspective review
Yamashima, T. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.004 · Cited by 116
Extracellular Vesicle Biology in Alzheimer’s Disease and Related Tauopathy
DeLeo, A. M., & Ikezu, T. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-017-9768-z · Cited by 106
Amyloid duration is associated with preclinical cognitive decline and tau PET
Koscik, R. L., Betthauser, T. J., Jonaitis, E. M., Allison, S. L., Clark, L. R., Hermann, B. P., Cody, K. A., Engle, J. W., Barnhart, T. E., Stone, C. K., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12007 · Cited by 101
Galea, E., Launay, N., Portero-Otin, M., Ruiz, M., Pamplona, R., Aubourg, P., Ferrer, I., & Pujol, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.005 · Cited by 108
Rodrigue, K. M., Daugherty, A. M., Haacke, E. M., & Raz, N. (2013) · Cerebral Cortex · doi:10.1093/cercor/bhs139 · Cited by 98
O’Dell, R. S., Mecca, A. P., Chen, M.-K., Naganawa, M., Toyonaga, T., Lu, Y., Godek, T. A., Harris, J. E., Bartlett, H. H., Banks, E. R., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00742-y · Cited by 104
Kilroy, E., Apostolova, L. G., Liu, C., Yan, L., Ringman, J. M., & Wang, D. J. J. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24246 · Cited by 111
Arterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study
Wang, Z., Das, S. R., Xie, S. X., Arnold, S. E., Detre, J. A., & Wolk, D. A. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.04.014 · Cited by 105
Brooks, L. G., & Loewenstein, D. A. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt52 · Cited by 102
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Redox proteomics and amyloid β-peptide: Insights into Alzheimer disease
Butterfield, D. A., & Boyd‐Kimball, D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14589 · Cited by 105
“Imaging studies indicate that increase in brain Ab(1–42) may begin up to 20 years prior to the onset of cognitive symptoms (Jack et al. 2009; Bateman et al. 2012; Reiman et al. 2012; Villemagne et al. 2013).”
BackgroundGrimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.013 · Cited by 101
Lee, M. J., Seo, S. W., Na, D. L., Kim, C., Park, J. H., Kim, G. H., Kim, C. H., Noh, Y., Cho, H., Kim, H. J., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4506 · Cited by 102
Self-citationLongitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriers
Caselli, R. J., Dueck, A. C., Locke, D. E. C., Hoffman-Snyder, C. R., Woodruff, B. K., Rapcsak, S. Z., & Reiman, E. M. (2011) · Neurology · doi:10.1212/wnl.0b013e3182167147 · Cited by 98
Ewers, M., Insel, P., Jagust, W. J., Shaw, L., Trojanowski J, J. Q., Aisen, P., Petersen, R. C., Schuff, N., Weiner, M. W., & (ADNI), F. T. A. D. N. I. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr271 · Cited by 97
Self-citationOh, H., Habeck, C., Madison, C., & Jagust, W. (2014) · Human Brain Mapping · doi:10.1002/hbm.22173 · Cited by 101
β-Amyloid affects frontal and posterior brain networks in normal aging
Oh, H., Mormino, E. C., Madison, C., Hayenga, A., Smiljic, A., & Jagust, W. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.027 · Cited by 103
Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
(2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 99
Leoni, V. (2011) · cclm · doi:10.1515/cclm.2011.088 · Cited by 100
Axonal Degeneration in AD: The Contribution of Aβ and Tau
Salvadores, N., Gerónimo-Olvera, C., & Court, F. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.581767 · Cited by 96
Ferreira, L. K., & Busatto, G. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300003 · Cited by 102
Longitudinal Patterns of β-Amyloid Deposition in Nondemented Older Adults
Sojkova, J., Zhou, Y., An, Y., Kraut, M. A., Ferrucci, L., Wong, D. F., & Resnick, S. M. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.77 · Cited by 99
β‐amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia
Müller, M. L. T. M., Frey, K. A., Petrou, M., Kotagal, V., Koeppe, R. A., Albin, R. L., & Bohnen, N. I. (2012) · Movement Disorders · doi:10.1002/mds.25213 · Cited by 110
Tosun, D., Schuff, N., Truran-Sacrey, D., Shaw, L. M., Trojanowski, J. Q., Aisen, P., Peterson, R., & Weiner, M. W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.030 · Cited by 98
Self-citationAmyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 88
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98
PET/CT in diagnosis of dementia
Berti, V., Pupi, A., & Mosconi, L. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06015.x · Cited by 95
Guercio, B. J., Donovan, N. J., Munro, C. E., Aghjayan, S. L., Wigman, S. E., Locascio, J. J., Amariglio, R. E., Rentz, D. M., Johnson, K. A., Sperling, R. A., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150146 · Cited by 88
White matter alterations in early‐stage Alzheimer's disease: A tract‐specific study
Wen, Q., Mustafi, S. M., Li, J., Risacher, S. L., Tallman, E., Brown, S. A., West, J. D., Harezlak, J., Farlow, M. R., Unverzagt, F. W., et al. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.06.003 · Cited by 96
King, K. S., Kozlitina, J., Rosenberg, R. N., Peshock, R. M., McColl, R. W., & Garcia, C. K. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1926 · Cited by 95
Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.
Arbor, S., LaFontaine, M., & Cumbay, M. G. (2016) · PubMed Central · Cited by 135
Rostomian, A. H., Madison, C. M., Rabinovici, G. D., & Jagust, W. J. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.082057 · Cited by 101
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
Self-citationAβ alters the connectivity of olfactory neurons in the absence of amyloid plaques in vivo
Cao, L., Schrank, B. R., Rodriguez, S., Benz, E. G., Moulia, T. W., Rickenbacher, G. T., Gomez, A. C., Levites, Y., Edwards, S. R., Golde, T. E., et al. (2012) · Nature Communications · doi:10.1038/ncomms2013 · Cited by 93
Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease
Lobello, K., Ryan, J. M., Liu, E., Rippon, G., & Black, R. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/628070 · Cited by 87
Variation in longevity gene KLOTHO is associated with greater cortical volumes
Yokoyama, J. S., Sturm, V. E., Bonham, L. W., Klein, E., Arfanakis, K., Yu, L., Coppola, G., Kramer, J. H., Bennett, D. A., Miller, B. L., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.161 · Cited by 90
Executive Dysfunction in MCI: Subtype or Early Symptom
Reinvang, I., Grambaitė, R., & Espeseth, T. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/936272 · Cited by 106
Can sleep apnea cause Alzheimer's disease?
Pan, W., & Kastin, A. J. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.10.019 · Cited by 98
Frings, L., Hellwig, S., Spehl, T. S., Bormann, T., Buchert, R., Vach, W., Minkova, L., Heimbach, B., Klöppel, S., & Meyer, P. T. (2015) · Brain · doi:10.1093/brain/awv229 · Cited by 91
Quantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, V. J., Lundt, E. S., Albertson, S. M., Przybelski, S. A., Senjem, M. L., Parisi, J. E., Kantarci, K., Boeve, B., Jones, D. T., Knopman, D., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.016 · Cited by 90
“Participants were part of the Mayo Clinic Study of Aging or Mayo Clinic Alzheimer’s Disease Research Center as described previously [38].”
MethodSelf-citationAssociation of Gray Matter Atrophy with Age, β-Amyloid, and Cognition in Aging
Oh, H., Madison, C., Villeneuve, S., Markley, C., & Jagust, W. J. (2014) · Cerebral Cortex · doi:10.1093/cercor/bht017 · Cited by 81
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
“…is likely to be the case, substantial cohorts of PIBpositive, cognitively intact subjects have not yet been followed for an extended period of time to determine the risk for conversion to AD (Fagan et al., 2005; Reiman et al., 2009; Jack et al., 2009; Mormino et al., 2008; Aizenstein et al., 2008).”
Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies
Sarro, L., Senjem, M. L., Lundt, E. S., Przybelski, S. A., Lesnick, T. G., Graff-Radford, J., Boeve, B. F., Lowe, V. J., Ferman, T. J., Knopman, D. S., et al. (2016) · Brain · doi:10.1093/brain/aww193 · Cited by 89
Self-citationIatrogenic Risk Factors for Alzheimer's Disease: Surgery and Anesthesia
Vanderweyde, T. E., Bednar, M. M., Forman, S. A., & Wolozin, B. L. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100843 · Cited by 91
Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns
Hwang, J., Kim, C. M., Jeon, S., Lee, J. M., Hong, Y. J., Roh, J. H., Lee, J., Koh, J., Na, D. L., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.008 · Cited by 84
Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease
Sintini, I., Martin, P. R., Graff-Radford, J., Senjem, M. L., Schwarz, C. G., Machulda, M. M., Spychalla, A. J., Drubach, D. A., Knopman, D. S., Petersen, R. C., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101823 · Cited by 83
Self-citationEffects of beta-amyloid accumulation on neural function during encoding across the adult lifespan
Kennedy, K. M., Rodrigue, K. M., Devous, M. D., Hebrank, A. C., Bischof, G. N., & Park, D. C. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.03.077 · Cited by 83
Rinne, J. O., Wong, D. F., Wolk, D. A., Leinonen, V., Arnold, S. E., Buckley, C. J., Smith, A. P. L., McLain, R. W., Sherwin, P. F., Farrar, G., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1051-z · Cited by 91
Plasma β-Amyloid and Cognitive Decline
Cosentino, S., Stern, Y., Sokolov, E., Scarmeas, N., Manly, J. J., Tang, M. X., Schupf, N., & Mayeux, R. P. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.189 · Cited by 90
Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease
Butterfield, D. A., & Boyd-Kimball, D. (2020) · Antioxidants · doi:10.3390/antiox9090818 · Cited by 85
Martí-Juan, G., Sanroma-Guell, G., & Piella, G. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105348 · Cited by 85
An Overview of PET Neuroimaging
Nasrallah, I. M., & Dubroff, J. G. (2013) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2013.06.003 · Cited by 92
Neuropathological assessment of the Alzheimer spectrum
Jellinger, K. A. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02232-9 · Cited by 89
González‐Martínez, Á., Rosado, B., Pesini, P., Suarez, M. L., Santamarina, G., García‐Belenguer, S., Villegas, A., Monleón, I., & Sarasa, M. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.02.013 · Cited by 93
Safety of disclosing amyloid status in cognitively normal older adults
Burns, J. M., Johnson, D. K., Liebmann, E. P., Bothwell, R. J., Morris, J. K., & Vidoni, E. D. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.022 · Cited by 85
Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension
Beaman, E. E., Bonde, A. N., Larsen, S. M. U., Ozenne, B., Lohela, T. J., Nedergaard, M., Gislason, G., Knudsen, G. M., & Holst, S. C. (2022) · Brain · doi:10.1093/brain/awac076 · Cited by 88
Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 85
Alzheimer's Disease and Amyloid: Culprit or Coincidence?
Skaper, S. D. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-386986-9.00011-9 · Cited by 91
Hua, X., Lee, S., Hibar, D. P., Yanovsky, I., Leow, A. D., Toga, A. W., Jack, C. R., Bernstein, M. A., Reiman, E. M., Harvey, D. J., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.01.104 · Cited by 85
Self-citation(ADNI), A. D. N. I., Nho, K., Risacher, S. L., Crane, P. K., DeCarli, C., Glymour, M. M., Habeck, C., Kim, S., Lee, G. J., Mormino, E., et al. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9203-2 · Cited by 78
Metadata
- Authors
- Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- San Francisco VA Medical Center (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-03-31
- Volume
- 132
- Issue
- 5
- Pages
- 1355-1365
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2677798
- OpenAlex
- W2133719476
- Cited by
- 1,099
- References
- 83
- Citations by year
- 2026: 29 · 2025: 28 · 2024: 34 · 2023: 51 · 2022: 45 · 2021: 49 · 2020: 60 · 2019: 54 · 2018: 62 · 2017: 46 · 2016: 56 · 2015: 69 · 2014: 73 · 2013: 94 · 2012: 116
- FWCI
- 71.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Mayo Foundation for Medical Education and Research (AG16574)
- National Institute for Health and Care Research (NF-SI-0508-10123)
- National Institute on Aging (R01AG11378, P01AG010491, P50‐AG16574, U01AG06786, AG 024904, R01AG027342, U01AG006786, R01AG011378, P30AG019610, U19AG010483, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, mild cognitive impairment, amyloid deposition, neurodegeneration, brain atrophy, ventriculomegaly, Pittsburgh compound B PET, serial imaging, amyloid plaques, cognitive decline, Alzheimer's Disease Neuroimaging Initiative, brain atrophy rate
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Atrophy, Brain, Carbon Radioisotopes, Cognition Disorders, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Time Factors, Case-Control Studies, Amyloid beta-Peptides, Statistics, Nonparametric, Radiopharmaceuticals, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.